This Selected Patent Portfolio Report provides a panoramic analysis of issued United States patents owned by Amgen, Inc. that recite claims to erythropoietin sequences, compositions and methods of manufacturing. Thirty-eight patents assigned to Amgen, Inc. are identified that relate to erythropoietin. Further analysis of these thirty-eight patents identified a subset of patents that recite claims to Amgen’s commercial product, Epogen (epoetin alfa). This report provides detailed analysis of each claim directed to erythropoietin as well as it’s overall coverage of Epogen.
The Report analyzes 43 issued U.S. patents believed to be owned or controlled by Osiris Therapeutics, Inc. (NASDAQ: OSIR). The Report features detailed claim charts for all independent claims of the Osiris patents, as well as a “portfolio” claim chart that presents all portfolio claim limitations in a single view. The Claim Charts, prepared by patent attorneys with expertise in stem cell technology include a detailed breakdown of functional claim limitations, including composition limitations, therapy limitations, cellular limitations, therapy limitations, cellular limitations, and manufacturing limitations relating to Osiris' steam cell products. The Interactive Clearance Chart also includes a “baseball card” chart of each individual patent providing a single patent view, and the full claim language. The report provides insights into strengths and limitations of Osiris’ patent coverage, and opportunities for follow-on or competing products. Data in the report is current through Q2 2009.
This comprehensive Stem Cell Industry Patent Report provides a panoramic claims-level analysis of the U.S. Stem Cell patent landscape. The Report evaluates 911 issued U.S. patents relating to stem cell technologies. Patents covered have been categorized by stem cell type or origin and by the therapeutic methods contemplated in the patent claims for treating diseases. The Report identifies, among other things, the distribution of patent holdings and the major competitors in the field.